News | July 31, 2007

BioControl Implants Congestive Heart Failure Device

August 1, 2007 - BioControl Medical announced that cardiologists at University Hospital Mannheim in Germany and at Ospedali Riuniti di Bergamo in Italy have successfully implanted the CardioFit device in the first patients to be enrolled at those sites in BioControl’s international, multi-center clinical study of the CardioFit system, marking an important step for the treatment of advanced congestive heart failure.

The CardioFit system works by applying electrical impulses to the vagus nerve. A sensing electrode in the right ventricle detects the patient’s heart rate and is used to control nerve stimulation.

The Bergamo and Mannheim hospitals join four other sites in Europe actively enrolling patients for the CardioFit system study that will include a total of 30 patients worldwide.

For more information: www.biocontrol-medical.com


Additional Content

Feature | EP Lab | Lars Thording, PhD

Medical device portfolios now move on two very different clocks. New technologies can gain clinical adoption within ...

Home October 14, 2026
Home
News | EP Lab

July 7, 2026 —AtaCor Medical has announced the enrollment of the first patient in the company's ALARION-EV trial ...

Home July 09, 2026
Home
News | EP Lab

April 17, 2026 — Corify Care has announced that the U.S. Food and Drug Administration (FDA) has granted clearance for ...

Home April 20, 2026
Home
News | EP Lab

Jan. 28, 2026 — Corify Care has announced a major development in cardiac electrophysiology with the publication of its ...

Home January 29, 2026
Home
News | EP Lab

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home April 29, 2025
Home
Subscribe Now